XTL BIOPHARMACEUTICALS LTD
Price data unavailable
Track XTLB in your trading journalAbout XTL BIOPHARMACEUTICALS LTD
XTL BIOPHARMACEUTICALS LTD (XTLB) is a publicly listed company on US equity markets.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Use FINOTAUR to track XTLB's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | — |
| Net Income (TTM) | — |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | — |
| Debt-to-Equity | — |
| Dividend per Share | — |
Recent News
- Benzinga·Jan 13
Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments
- Benzinga·Jan 13
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
- Investing.com·Jul 22
XTL Biopharmaceuticals Confirms Board and Auditor Appointments - Investing.com
Want real-time analysis on XTLB?
Track it free in your trading journal. Log trades, tag setups, and review your edge.